Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a single drug infusion limit permanent heart damage during a heart attack?

NCT ID NCT07502521

Disease control Sponsor: Rohan Dharmakumar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a drug called dexrazoxane, given through a vein, can reduce permanent heart muscle damage in people having a severe heart attack (STEMI). Fifty adults received either the drug or a placebo during their standard stent procedure. The goal was to see if the drug could limit bleeding and scarring in the heart, helping it pump better afterward.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

50 people

The number who actually took part.

Started

Aug 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria - 1. Adult (18 - 79 years). 2. First STEMI (EMS/ER ECG ST-elevation) with primary PCI planned. 3. Consent pathway available: Patient consent, Legally Acceptable Representative (LAR) 4. CMR likely be feasible (no known MRI-unsafe implant or absolute MRI prohibition) Exclusion Criteria - 1. History of PCI or CABG within 1 year 2. Known dialysis/ESRD 3. Known pre-existing LVEF \<40% from recent records 4. Known pregnancy or breastfeeding (history or clearly documented) 5. Current anthracycline chemotherapy or active chest radiation (per patient/chart). 6. On iron chelation now or documented iron-storage disease (hemochromatosis/thalassemia). 7. Concurrent trials: investigational drug or device use within 90 days. 8. Any clinically significant condition identified that would preclude safe peri-procedural administration of Dexrazoxane or completion of core protocol procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction (AMI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction (AMI)

Contacts and locations

Locations

  • Synergy Cardiovascular Research Center

    Rajkot, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.